Giachetti C, Bertolino M, Canali S, Lombardini E, Monzani M V, Sala A, Zanolo G
Istituto di Ricerche Biomediche A. Marxer, RBM S.p.A., Colleretto Giacosa (TO), Italy.
Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):230-8. doi: 10.1007/BF03189345.
Pharmacokinetics of [14C]-ITF-296 and its metabolites, ITF-1124 and ITF-1577, were studied in rats after a single intravenous (2.5 mg/kg) and oral (10 mg/kg) administration. Radioactivity was measured by LSC while unchanged drug and its metabolites in plasma were assayed by an HPLC-UV method. The absorption of [14C]-ITF-296 after oral administration is practically complete. Elimination of radioactivity occurs mainly in urine (higher than 80%) and the recovery of the dose (higher than 95%) takes place up to 96 h after both treatments. Both by i.v. and p.o. route the results show that the radioactivity is largely excreted in the bile and reabsorbed in the intestine. The tissue distribution study indicates that there is no accumulation or localization of radioactivity in the major organs or blood and no radioactivity levels are found 96 h after either treatment. In addition, whole body autoradiography confirms the tissue distribution pattern, showing no differences between albino and pigmented rats.
在大鼠单次静脉注射(2.5毫克/千克)和口服(10毫克/千克)给药后,研究了[14C]-ITF-296及其代谢产物ITF-1124和ITF-1577的药代动力学。通过液体闪烁计数法测量放射性,而血浆中未变化的药物及其代谢产物则通过高效液相色谱-紫外法进行测定。口服给药后,[14C]-ITF-296的吸收几乎是完全的。放射性的消除主要发生在尿液中(高于80%),两种给药方式后,在96小时内剂量回收率(高于95%)。静脉注射和口服途径的结果均表明,放射性物质大量经胆汁排泄并在肠道重吸收。组织分布研究表明,主要器官或血液中没有放射性物质的积累或定位,两种给药后96小时均未发现放射性水平。此外,全身放射自显影证实了组织分布模式,显示白化大鼠和有色大鼠之间没有差异。